Results 291 to 300 of about 22,236,668 (323)
Some of the next articles are maybe not open access.

Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trials

Investigational New Drugs, 2017
Regorafenib (Stivarga) is an oral small-molecule multikinase inhibitor commonly used against a variety of cancers. We performed a meta-analysis of all phase 3 randomized controlled trials (RCTs) of regorafenib to quantify the increased risk of SAEs and FAEs. We carried out a systematic search of electronic databases for studies published from inception
Meihui Cao   +3 more
openaire   +2 more sources

Tongue discoloration in an elderly kidney transplant recipient: Treatment-related adverse event?

The American Journal of Geriatric Pharmacotherapy, 2006
With the increased occurrence of methicillin-resistant staphylococcus aureus infections, linezolid treatment might be administered more often. New rare adverse events are likely to follow.A 65-year-old man (weight, 91 kg; height, 185 cm) presented to the emergency department at the University of Virginia-affiliated Salem Veterans Affairs Medical Center,
Khalil A, Amir   +6 more
openaire   +2 more sources

Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis.

The Lancet Oncology, 2021
Xiaoxiang Zhou   +15 more
semanticscholar   +1 more source

Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis

Journal of Chemotherapy, 2013
Cetuximab has been approved by FDA for the treatment of advanced/metastatic colorectal cancer. Whether cetuximab treatment is associated with an increase of severe adverse events in colorectal cancer (CRC) patients remains a question. The purpose is to assess the risk of severe adverse events of cetuximab treatment in advanced/metastatic CRC patients ...
Di, Zhang   +3 more
openaire   +2 more sources

Association Between Frailty and Short‐Term Treatment‐Related Adverse Events in Patients With Overactive Bladder

LUTS: Lower Urinary Tract Symptoms
ABSTRACT Objectives To evaluate whether frailty at treatment initiation is associated with treatment‐related adverse events in patients with newly diagnosed overactive bladder (OAB). Methods This retrospective, single‐
Sohei Iwagami   +3 more
openaire   +4 more sources

Sinonasal mucosal melanoma: An analysis of treatment‐related adverse events and associated factors

International Forum of Allergy & Rhinology, 2022
Brian J. Johnson   +18 more
openaire   +2 more sources

Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials

Journal of Clinical Oncology
PURPOSE Retrospective studies suggest that immunosuppressive treatment of immune-related adverse events (irAEs) impairs survival in patients with melanoma who received immune checkpoint inhibitors. Here, we study this association across tumor types using
R. Verheijden   +5 more
semanticscholar   +1 more source

Immune-Related Adverse Events of Immune Checkpoint Inhibitors

Annals of Internal Medicine
Immune-related adverse events (irAEs) are toxicities that arise after the administration of monoclonal antibodies targeting immune checkpoints (immune checkpoint inhibitors [ICIs]) in patients with cancer.
M. Ramos-Casals, A. Sisó-Almirall
semanticscholar   +1 more source

Abstract 2749: Towards a foundation model for treatment-related adverse events in cancer immunotherapy.

Cancer Research
Abstract Background: Immune-related adverse events (irAEs) provide important clues about immune activation during checkpoint blockade, yet real-world AE reporting is often sparse and fragmented. A further challenge is that FAERS provides unstructured case-level reports, while ClinicalTrials.gov
Bin Baek   +4 more
openaire   +1 more source

A bibliometric analysis of immune-related adverse events in cancer patients and a meta-analysis of immune-related adverse events in patients with hepatocellular carcinoma

Journal of Translational Internal Medicine
Background and Objectives Immunotherapy has become the standard treatment for hepatocellular carcinoma (HCC), but it carries a risk of immune-related adverse events (irAEs) that can be life-threatening.
Bengang Wang   +5 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy